Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 213 Show results per page	View Search Criteria \| Help With Results


1.		Phase II/III Chemotherapy with DNM/ARA-C Induction and DNM/ARA-C/TG, DNM/AZC, and ARA-C/TG Maintenance for Acute Myelogenous Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Completed				under 60								NCI-D81-018-590 DFCI-80035


2.		Phase II/III Consolidation Chemotherapy with VP-16/AMSA/AZC Following Induction with DNM/ARA-C/TG for Adult Primary or Secondary Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				18 and over								NCI-D82-051-605

Last Modified: 8/10/2007


3.		Phase II/III Pilot Combination Chemotherapy and Radiotherapy for Previously Untreated Childhood ALL with Poor Prognosis

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Completed				under 21				NCI				CCG-192P

Last Modified: 5/21/2007


4.		Phase II and III Chemotherapy with 5-FU, CTX, TG, MeCCNU and TGDR for Advanced Colon and Rectal Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Completed				no age specified				NCI				EST-4273

Last Modified: 4/10/2008


5.		Phase III Randomized Study of Induction and Intensification Regimens for Childhood Acute Myeloid Leukemia: IDA vs DNR with ARA-C/VP-16 for Induction in All Patients and Intensification with High-Dose ARA-C/DHAD (HAM) Before vs After Consolidation in High-Risk Patients

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				under 17								GER-GPOH-AML-BFM-93 EU-93008

Last Modified: 5/24/2006


6.		Phase III Randomized Study of Bone Marrow Transplantation vs Prolonged Intensive Chemotherapy Following Remission Re-Induction after Early First Marrow Relapse in Children with Acute Lymphocytic Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				at least 1 + under 20 at diag.				NCI				CCG-1941

Last Modified: 5/16/2008


7.		Phase III Study of Treatment for Childhood Acute Myeloid Leukemia: High vs Standard Dose Cytarabine in the Daunorubicin, Cytarabine, Thioguanine Induction Regimen, Multidrug Resistance (MDR) Modulation with Cyclosporine vs No MDR Modulation During Consolidation, and a Comparison of Allogeneic Bone Marrow Transplant and Consolidative Chemotherapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				under 21				NCI				POG-9421

Last Modified: 2/26/2008 First Published: 6/1/1995


8.		Phase III Randomized Study of Two Induction Courses That Include Daunorubicin vs Mitoxantrone and Filgrastim (G-CSF) vs Placebo, Followed By MACE (Amsacrine, Cytarabine, and Etoposide), Then Bone Marrow Transplantation (BMT) vs MidAC (Mitoxantrone and Cytarabine) vs ICE (Idarubicin, Cytarabine, and Etoposide) Followed By BMT vs ICE Followed By MidAC in Patients With Acute Myeloid Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				15 to physiologic 59				Other				MRC-LEUK-AML12 EU-95001, NCT00002658

Last Modified: 11/29/2006 First Published: 1/1/1996


9.		Phase III Randomized Study of Induction Using Tretinoin (ATRA) and Idarubicin (IDA), 3 Sequential Consolidation Regimens Using Cytarabine Plus IDA, Followed by Mitoxantrone Plus Etoposide, and then IDA, Cytarabine, and Thioguanine, and Maintenance Using Mercaptopurine (MP) Plus Methotrexate (MTX) Versus ATRA Only Versus MP Plus MTX Alternating With ATRA Versus Observation Only With or Without Bone Marrow Transplantation in Patients With Acute Promyelocytic Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				16 to 74								EORTC-06952 ITA-GIMEMA-AIEOP-1, NCT00002701

Last Modified: 12/20/2007


10.		Phase III Randomized Study of Oral Mercaptopurine vs Oral Thioguanine and of Intrathecal MTX vs Triple Intrathecal Chemotherapy (Methotrexate, Catarabine, and Hydrocortisone) During Consolidation, Interim Maintenance, and Maintenance for Newly Diagnosed Standard Risk Childhood Acute Lymphoblastic Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				1 to 9				NCI				CCG-1952 NCT00002744

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute